Associations - ER positive

ER positive ER positive	Uterine Cancer Uterine Cancer	ER positive ER positive	Uterine Cancer Uterine Cancer	anastrozole Sensitive: C3 – Early Trials Gynecol Oncol - 2 weeks	anastrozole Sensitive: C3 – Early Trials Gynecol Oncol - 2 weeks
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials Gynecol Oncol - 2 weeks	anastrozole Sensitive: C3 – Early Trials Gynecol Oncol - 2 weeks
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval	fulvestrant Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	exemestane Sensitive: A1 - Approval	exemestane Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	toremifene Sensitive: A1 - Approval	toremifene Sensitive: A1 - Approval
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline	trastuzumab + lapatinib Sensitive: A2 - Guideline
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline	letrozole Sensitive: A2 - Guideline
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline	Aromatase inhibitor Sensitive: A2 - Guideline
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline	anastrozole Sensitive: A2 - Guideline
ER positive ER positive	Male Breast Cancer Male Breast Cancer	ER positive ER positive	Male Breast Cancer Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline	tamoxifen Sensitive: A2 - Guideline
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	neratinib Sensitive: A2 - Guideline	neratinib Sensitive: A2 - Guideline
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline	medroxyprogesterone Sensitive: A2 - Guideline
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline	megestrol Sensitive: A2 - Guideline
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	gimeracil/oteracil/tegafur Sensitive: B - Late Trials	gimeracil/oteracil/tegafur Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials	palbociclib Sensitive: B - Late Trials
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials	trastuzumab Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials	GDC-0032 Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	EC-P Sensitive: B - Late Trials	EC-P Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	exemestane Sensitive: C1 - Off-label	exemestane Sensitive: C1 - Off-label
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: C1 - Off-label	fulvestrant Sensitive: C1 - Off-label
ER positive ER positive	Breast Cancer Breast Cancer	ER positive ER positive	Breast Cancer Breast Cancer	capecitabine Sensitive: C2 – Inclusion Criteria	capecitabine Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	SAR439859 Sensitive: C2 – Inclusion Criteria	SAR439859 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Ovarian Cancer Ovarian Cancer	ER positive ER positive	Ovarian Cancer Ovarian Cancer	ribociclib Sensitive: C2 – Inclusion Criteria	ribociclib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	G1T48 Sensitive: C2 – Inclusion Criteria	G1T48 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	capecitabine Sensitive: C2 – Inclusion Criteria	capecitabine Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	TAK-228 Sensitive: C2 – Inclusion Criteria	TAK-228 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	H3B-6545 Sensitive: C2 – Inclusion Criteria	H3B-6545 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Endometrial Cancer Endometrial Cancer	ER positive ER positive	Endometrial Cancer Endometrial Cancer	ribociclib + letrozole Sensitive: C2 – Inclusion Criteria	ribociclib + letrozole Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Breast Cancer Breast Cancer	ER positive ER positive	Breast Cancer Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: C2 – Inclusion Criteria	ribociclib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria	alpelisib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	AZD9833 Sensitive: C2 – Inclusion Criteria	AZD9833 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: C2 – Inclusion Criteria	palbociclib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	everolimus Sensitive: C2 – Inclusion Criteria	everolimus Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	trastuzumab Sensitive: C2 – Inclusion Criteria	trastuzumab Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C2 – Inclusion Criteria	palbociclib + PF-05212384 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Breast Cancer Breast Cancer	ER positive ER positive	Breast Cancer Breast Cancer	tamoxifen Sensitive: C2 – Inclusion Criteria	tamoxifen Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib + GDC-9545 Sensitive: C2 – Inclusion Criteria	palbociclib + GDC-9545 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	bevacizumab Sensitive: C3 – Early Trials	bevacizumab Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	enobosarm Sensitive: C3 – Early Trials	enobosarm Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	AC Sensitive: C3 – Early Trials	AC Sensitive: C3 – Early Trials
ER positive ER positive	Endometrial Cancer Endometrial Cancer	ER positive ER positive	Endometrial Cancer Endometrial Cancer	palbociclib + letrozole Sensitive: C3 – Early Trials	palbociclib + letrozole Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ZN-c5 Sensitive: C3 – Early Trials	ZN-c5 Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen + TAK-228 Sensitive: C3 – Early Trials	tamoxifen + TAK-228 Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	lapatinib Resistant: C3 – Early Trials	lapatinib Resistant: C3 – Early Trials
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + palbociclib Sensitive: C3 – Early Trials	trastuzumab + palbociclib Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen + GDC-0032 Sensitive: C3 – Early Trials	tamoxifen + GDC-0032 Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ribociclib Sensitive: C3 – Early Trials	ribociclib Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	lapatinib + ado-trastuzumab emtansine Sensitive: C3 – Early Trials	lapatinib + ado-trastuzumab emtansine Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	zoledronic acid Resistant: C3 – Early Trials	zoledronic acid Resistant: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ixazomib Sensitive: C3 – Early Trials	ixazomib Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ponatinib Sensitive: C3 – Early Trials	ponatinib Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ARV-471 Sensitive: C3 – Early Trials	ARV-471 Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	MLN8237 Sensitive: C3 – Early Trials	MLN8237 Sensitive: C3 – Early Trials
ER positive ER positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ER positive ER positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ado-trastuzumab emtansine + pertuzumab Sensitive: C3 – Early Trials	ado-trastuzumab emtansine + pertuzumab Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	LY3484356 Sensitive: C3 – Early Trials	LY3484356 Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	venetoclax Resistant: C3 – Early Trials	venetoclax Resistant: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	sunitinib Sensitive: C3 – Early Trials	sunitinib Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	RAD140 Sensitive: C3 – Early Trials	RAD140 Sensitive: C3 – Early Trials
ER positive ER positive	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	ER positive ER positive	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	letrozole + zoledronic acid Sensitive: C4 – Case Studies	letrozole + zoledronic acid Sensitive: C4 – Case Studies
ER positive ER positive	Gastric Cancer Gastric Cancer	ER positive ER positive	Gastric Cancer Gastric Cancer	letrozole Sensitive: C4 – Case Studies	letrozole Sensitive: C4 – Case Studies
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	apalutamide Sensitive: D – Preclinical	apalutamide Sensitive: D – Preclinical
ER positive ER positive	Ovarian Cancer Ovarian Cancer	ER positive ER positive	Ovarian Cancer Ovarian Cancer	abemaciclib Sensitive: D – Preclinical	abemaciclib Sensitive: D – Preclinical
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	doxorubicin hydrochloride Resistant: D – Preclinical	doxorubicin hydrochloride Resistant: D – Preclinical
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	docetaxel Resistant: D – Preclinical	docetaxel Resistant: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	RGT-419B Sensitive: D – Preclinical	RGT-419B Sensitive: D – Preclinical
ER positive ER positive	Endometrial Cancer Endometrial Cancer	ER positive ER positive	Endometrial Cancer Endometrial Cancer	abemaciclib + letrozole Sensitive: D – Preclinical	abemaciclib + letrozole Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	MLN4924 Sensitive: D – Preclinical	MLN4924 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + CGM097 Sensitive: D – Preclinical	palbociclib + CGM097 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CGM097 Sensitive: D – Preclinical	CGM097 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	levo-tetrahydropalmatine Sensitive: D – Preclinical	levo-tetrahydropalmatine Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	MK-2206 + D9 Sensitive: D – Preclinical	MK-2206 + D9 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	SNG-162 Sensitive: D – Preclinical	SNG-162 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + CR-1-31-B Sensitive: D – Preclinical	palbociclib + CR-1-31-B Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	darolutamide Sensitive: D – Preclinical	darolutamide Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	enzalutamide Sensitive: D – Preclinical	enzalutamide Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	abemaciclib Sensitive: D – Preclinical	abemaciclib Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + ZEN-3694 Sensitive: D – Preclinical	palbociclib + ZEN-3694 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	abemaciclib + ZEN-3694 Sensitive: D – Preclinical	abemaciclib + ZEN-3694 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + APG-2575 Sensitive: D – Preclinical	palbociclib + APG-2575 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	paclitaxel + eribulin mesylate Sensitive: D – Preclinical	paclitaxel + eribulin mesylate Sensitive: D – Preclinical
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	XMT-1660 Sensitive: D – Preclinical	XMT-1660 Sensitive: D – Preclinical
ER positive ER positive	Breast Cancer Breast Cancer	ER positive ER positive	Breast Cancer Breast Cancer	everolimus + alpelisib + abemaciclib + LY3484356 Sensitive: D – Preclinical	everolimus + alpelisib + abemaciclib + LY3484356 Sensitive: D – Preclinical
ER positive ER positive	Breast Cancer Breast Cancer	ER positive ER positive	Breast Cancer Breast Cancer	LY3484356 Sensitive: D – Preclinical	LY3484356 Sensitive: D – Preclinical
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	Q901 Sensitive: D – Preclinical	Q901 Sensitive: D – Preclinical
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	E7090 Sensitive: D – Preclinical	E7090 Sensitive: D – Preclinical
ER positive ER positive	Breast Cancer Breast Cancer	ER positive ER positive	Breast Cancer Breast Cancer	SCR6106 Sensitive: D – Preclinical	SCR6106 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	sorafenib Sensitive: D – Preclinical	sorafenib Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	metformin Sensitive: D – Preclinical	metformin Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: D – Preclinical	tamoxifen Resistant: D – Preclinical
ER positive ER positive	Breast Cancer Breast Cancer	ER positive ER positive	Breast Cancer Breast Cancer	ZEN-3694 Sensitive: D – Preclinical	ZEN-3694 Sensitive: D – Preclinical